Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

Date

2020-06

Dewey

Economie sociale

Sujet

Anticoagulants; atrial fibrillation; cost-effectiveness; economic; real-world evidence; stroke prevention

JEL code

I.I1.I18; I.I1.I12

Journal issue

Journal of Market Access & Health Policy

Volume

8

Number

1

Publication date

06-2020

Article pages

1782164

Publisher

Taylor & Francis

DOI

http://dx.doi.org/10.1080/20016689.2020.1782164

URI

https://basepub.dauphine.fr/handle/123456789/21537

Collections

• LEDa : Publications

Metadata

Show full item record

Author

Bowrin, Kevin

167303 Bayer Corporation

Briere, Jean-Baptiste

73660 BAYER AG

Lévy, Pierre

163517 Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
559342 Laboratoire d'Economie de Dauphine [LEDa]

Millier, Aurélie

147877 Creativ-Ceutical France

Tardu, Jean

147877 Creativ-Ceutical France

Toumi, Mondher

527022 Centre d'études et de recherche sur les services de santé et la qualité de vie [CEReSS]

Type

Article accepté pour publication ou publié